| HER-2/neu as a target for cancer vaccines. | |
| | |
MedLine Citation:
|
PMID: 20635929 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A novel modality toward the treatment of HER-2/neu-positive malignancies, mostly including breast and, more recently prostate carcinomas, has been the use of vaccines targeting HER-2/neu extracellular and intracellular domains. HER-2/neu-specific vaccines have been demonstrated to generate durable T-cell anti-HER-2/neu immunity when tested in Phase I and II clinical trials with no significant toxicity or autoimmunity directed against normal tissues. Targeting of HER-2/neu in active immunotherapy may involve peptide and DNA vaccines. Moreover, active anti-HER-2/neu immunization could facilitate the ex vivo expansion of HER-2/neu-specific T cells for use in adoptive immunotherapy for the treatment of established metastatic disease. In addition, early data from trials examining the potential use of HER-2/neu-based vaccines in the adjuvant setting to prevent the relapse of breast cancer in high-risk patients have shown promising results. Future approaches include multiepitope preventive vaccines and combinatorial treatments for generating the most efficient protective anti-tumor immunity. |
| | |
Authors:
|
Constantin N Baxevanis; Ioannis F Voutsas; Angelos D Gritzapis; Sonia A Perez; Michael Papamichail |
Related Documents
:
|
10699939 - Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic... 11120809 - Reactivity and regulatory properties of human anti-idiotypic antibodies induced by t ce... 10490989 - Dendritic cell (dc)-based anti-infective strategies: dcs engineered to secrete il-12 ar... 20562209 - A viral vaccine encoding prostate-specific antigen induces antigen spreading to a commo... 19895199 - Vaccine therapy with dendritic cells transfected with il13ra2 mrna for glioma in mice. 17616639 - Il-2 immunotoxin denileukin diftitox reduces regulatory t cells and enhances vaccine-me... 10160489 - French economic evaluations of influenza and influenza vaccination. 17084489 - Measles vaccination of macaques by dry powder inhalation. 7989729 - Improving hepatitis b vaccination rates among surgeons. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Immunotherapy Volume: 2 ISSN: 1750-7448 ISO Abbreviation: Immunotherapy Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-07-19 Completed Date: 2010-11-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101485158 Medline TA: Immunotherapy Country: England |
Other Details:
|
Languages: eng Pagination: 213-26 Citation Subset: IM |
Affiliation:
|
Cancer Immunology & Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece. baxevanis@ciic.gr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antigens, Neoplasm / immunology* Cancer Vaccines / adverse effects, immunology* Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Forecasting Genes, erbB-2 Humans Immunotherapy, Active* Immunotherapy, Adoptive Mice Mice, Inbred BALB C Neoplasms / immunology, therapy Peptide Fragments / administration & dosage, immunology Receptor, erbB-2 / immunology* T-Lymphocytes, Cytotoxic / immunology, transplantation T-Lymphocytes, Helper-Inducer / immunology Vaccines, DNA / therapeutic use Vaccines, Subunit / therapeutic use Vaccines, Synthetic / immunology, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, Neoplasm; 0/Cancer Vaccines; 0/HER-2 peptide E75 (369-377), human; 0/Peptide Fragments; 0/Vaccines, DNA; 0/Vaccines, Subunit; 0/Vaccines, Synthetic; EC 2.7.10.1/ERBB2 protein, human; EC 2.7.10.1/Receptor, erbB-2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating ce...
Next Document: Immunotherapy of chronic myeloid leukemia: present state and future prospects.